Latest Ratios: P/E Ratio -2.3x · EV/EBITDA 9.0x · ROE -41.4%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.7B | $1.3B | $3.7B | $7.1B | $7.5B | $5.5B | $4.5B | $2.9B | $2.2B | $2.8B | $2.8B |
| Enterprise Value | $5.2B | $3.8B | $5.7B | $8.5B | $9.0B | $7.0B | $7.3B | $6.1B | $5.4B | $6.0B | $6.1B |
| P/E Ratio → | -2.34 | — | 14.26 | — | 27.62 | 28.90 | — | 26.79 | — | 14.19 | 472.86 |
| P/S Ratio | 0.80 | 0.39 | 1.16 | 2.41 | 2.89 | 2.38 | 2.13 | 1.45 | 0.74 | 1.00 | 1.01 |
| P/B Ratio | 1.21 | 0.60 | 1.14 | 2.45 | 2.60 | 2.13 | 2.34 | 1.16 | 0.95 | 1.09 | 1.30 |
| P/FCF | — | — | — | 185.10 | 89.28 | 42.50 | 10.07 | 60.50 | 30.90 | 22.65 | 52.69 |
| P/OCF | 20.12 | 9.76 | 28.14 | 15.30 | 19.80 | 14.72 | 6.76 | 8.76 | 5.42 | 7.11 | 7.87 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.15 | 1.79 | 2.90 | 3.44 | 3.03 | 3.51 | 3.02 | 1.79 | 2.12 | 2.16 |
| EV / EBITDA | 8.97 | 6.60 | 8.42 | 13.28 | 15.32 | 13.46 | 16.77 | 8.10 | 9.43 | 10.35 | 10.47 |
| EV / EBIT | 13.34 | — | 12.35 | 149.44 | 20.20 | 19.89 | 21.44 | 19.34 | 21.38 | 13.73 | 13.65 |
| EV / FCF | — | — | — | 222.02 | 106.24 | 54.11 | 16.58 | 125.97 | 74.18 | 47.95 | 112.51 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.6% | 17.6% | 22.6% | 23.3% | 96.2% | 96.1% | 95.8% | 40.6% | 41.0% | 41.8% | 41.0% |
| Operating Margin | 11.7% | 11.7% | 16.6% | 17.3% | 17.9% | 17.9% | — | 32.9% | 13.7% | 15.4% | 15.8% |
| Net Profit Margin | -33.3% | -33.3% | 8.1% | -0.7% | 10.5% | 8.2% | -32.2% | 5.4% | -5.8% | 7.0% | 0.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.4% | -41.4% | 8.4% | -0.7% | 10.0% | 8.5% | -30.5% | 4.5% | -7.1% | 8.4% | 0.3% |
| ROA | -19.2% | -19.2% | 4.5% | -0.4% | 5.6% | 3.4% | -10.0% | 1.7% | -2.8% | 3.2% | 0.1% |
| ROIC | 5.9% | 5.9% | 8.2% | 8.8% | 8.3% | 7.0% | — | 8.9% | 5.5% | 5.9% | 7.1% |
| ROCE | 7.5% | 7.5% | 10.6% | 11.2% | 10.4% | 8.7% | — | 10.9% | 7.0% | 7.5% | 9.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.24 | 1.24 | 0.65 | 0.52 | 0.53 | 0.63 | 1.71 | 1.30 | 1.35 | 1.25 | 1.50 |
| Debt / EBITDA | 4.60 | 4.60 | 3.10 | 2.36 | 2.61 | 3.14 | 7.45 | 4.35 | 5.59 | 5.58 | 5.67 |
| Net Debt / Equity | — | 1.18 | 0.63 | 0.49 | 0.49 | 0.58 | 1.52 | 1.26 | 1.33 | 1.22 | 1.48 |
| Net Debt / EBITDA | 4.37 | 4.37 | 2.99 | 2.21 | 2.45 | 2.89 | 6.59 | 4.21 | 5.50 | 5.46 | 5.57 |
| Debt / FCF | — | — | — | 36.92 | 16.96 | 11.60 | 6.51 | 65.47 | 43.28 | 25.30 | 59.82 |
| Interest Coverage | -6.68 | -6.68 | 3.94 | 0.69 | 6.36 | 4.58 | 2.16 | 1.68 | 1.36 | 2.49 | 2.45 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.55 | 1.55 | 1.00 | 0.67 | 1.30 | 1.22 | 1.93 | 1.17 | 1.08 | 1.25 | 1.25 |
| Quick Ratio | 1.54 | 1.54 | 0.99 | 0.67 | 1.29 | 1.21 | 1.93 | 1.16 | 1.07 | 1.24 | 1.23 |
| Cash Ratio | 0.25 | 0.25 | 0.13 | 0.11 | 0.25 | 0.33 | 0.29 | 0.21 | 0.12 | 0.18 | 0.17 |
| Asset Turnover | — | 0.60 | 0.53 | 0.55 | 0.52 | 0.49 | 0.32 | 0.29 | 0.49 | 0.44 | 0.47 |
| Inventory Turnover | 480.01 | 480.01 | 431.90 | 423.80 | 19.70 | 18.95 | 17.98 | 292.73 | 351.86 | 344.81 | 358.14 |
| Days Sales Outstanding | — | 60.07 | 48.83 | 53.53 | 49.46 | 48.01 | 51.88 | 58.35 | 38.54 | 44.39 | 40.87 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 7.0% | — | 3.6% | 3.5% | — | 3.7% | — | 7.0% | 0.2% |
| FCF Yield | — | — | — | 0.5% | 1.1% | 2.4% | 9.9% | 1.7% | 3.2% | 4.4% | 1.9% |
| Buyback Yield | 1.9% | 3.9% | 0.2% | 0.7% | 0.0% | 0.1% | 0.0% | 0.1% | 0.2% | 0.1% | 0.0% |
| Total Shareholder Yield | 1.9% | 3.9% | 0.2% | 0.7% | 0.0% | 0.1% | 0.0% | 0.1% | 0.2% | 0.1% | 0.0% |
| Shares Outstanding | — | $91M | $92M | $91M | $92M | $91M | $89M | $88M | $87M | $87M | $86M |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACHC stock.
Acadia Healthcare Company, Inc.'s current P/E ratio is -2.3x. The historical average is 32.0x.
Acadia Healthcare Company, Inc.'s current EV/EBITDA is 9.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.5x.
Acadia Healthcare Company, Inc.'s return on equity (ROE) is -41.4%. The historical average is -2.5%.
Based on historical data, Acadia Healthcare Company, Inc. is trading at a P/E of -2.3x. Compare with industry peers and growth rates for a complete picture.
Acadia Healthcare Company, Inc. has 17.6% gross margin and 11.7% operating margin. Operating margin between 10-20% is typical for established companies.
Acadia Healthcare Company, Inc.'s Debt/EBITDA ratio is 4.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Labor shortages and litigation
Metrics are mathematically derived from official filings.
Margin Volatility Masks Core Pressures
Gross margin swung from 96.7% in Q2 2025 to 16.6% in Q2 2026, reflecting cost reclassification; operating margin fell to 10.1%, indicating labor inflation and fixed reimbursement caps, as per quarterly filings.
The dramatic gross margin swing is largely a classification artifact, but the underlying trend is clear: operating margin has compressed from 17.9% in Q2 2024 to 10.1% in Q2 2026, even as revenue remained flat. This suggests that labor costs and other operating expenses are consuming a larger share of each dollar of revenue, consistent with the industry-wide nursing shortage and mandatory staffing ratios. The TTM net margin of -33.3% is heavily distorted by a massive non-recurring charge in Q4 2025, likely a legal settlement or impairment, which masks the underlying operational profitability that appears to be in the low-to-mid single digits on a net basis.
Return on Capital Decays Sharply
ROIC fell from 2.2% in Q2 2024 to 1.4% in Q2 2026, while ROE dropped from 2.6% to 0.5%, indicating that capital deployed is generating diminishing returns, as reported in financial statements.
The decline in ROIC and ROE is not just a function of the one-time loss; even excluding Q4 2025, the trend is downward. In Q2 2024, ROIC was 2.2%, and by Q2 2026 it had fallen to 1.4%, despite a growing asset base. This suggests that new investments, particularly in JV facilities, are not yet generating returns commensurate with their cost, or that existing assets are becoming less productive due to staffing constraints. The company's heavy investment in PPE (up to $3.2B) without corresponding revenue growth implies that capacity is not being fully utilized, likely because unstaffed beds generate no revenue.
Working Capital Efficiency Distorted by Payables
CCC swung from -608 days in Q2 2025 to +41 days in Q2 2026, driven by a collapse in DPO from 676 to 17 days, indicating a normalization of payment terms, based on reported figures.
The extreme negative CCC in 2024 and early 2025 was an artifact of unusually high DPO, which likely reflected delayed payments or accounting anomalies. The recent normalization to a positive CCC of 41 days is more typical for a healthcare provider, but it also means that Acadia can no longer rely on supplier financing to fund its operations. DSO has remained stable around 53-59 days, suggesting consistent billing and collection practices. The sharp reduction in DPO may indicate a shift in vendor relationships or a need to pay more promptly to secure scarce clinical supplies and labor, which could pressure cash flow.
Leverage Climbs as Debt Service Tightens
D/E rose from 0.64 in Q2 2024 to 1.17 in Q2 2026, while interest coverage fell from 4.65x to 3.30x, indicating reduced financial flexibility, as per recent balance sheet data.
The increase in leverage is partly due to the erosion of equity from the Q4 2025 loss, but total debt also grew from $2.0B to $2.6B over the same period. Interest coverage of 3.3x is still adequate but has deteriorated from 4.65x, and the D/EBITDA ratio of 18.55x is extremely high, though this is distorted by the depressed EBITDA from the one-time charge. Excluding that charge, D/EBITDA would be closer to 5-6x, which is more manageable. However, the trend is concerning: the company is taking on more debt while its earnings power is weakening, which could strain debt service if interest rates remain elevated.
Liquidity Improves but Cash Buffer Thin
Current ratio improved to 1.57 in Q2 2026 from 1.18 in Q2 2024, yet cash of $171M covers only 8% of total debt, indicating a modest liquidity cushion, as reported in financial statements.
The current ratio is healthy, and the quick ratio of 1.56 suggests that inventory is not a significant liquidity concern, which is typical for a service business. However, the absolute cash balance is small relative to the debt load, and the company's reliance on operating cash flow to service debt is evident. In Q2 2026, operating cash flow of $162.1M was strong, but it is volatile, as seen in the negative FCF margins in prior quarters. Under a severe stress scenario—such as a prolonged labor shortage or a large legal settlement—the liquidity position could deteriorate quickly, given the thin cash buffer.
EV/EBITDA Misleads on Earnings Quality
The most misapplied ratio is EV/EBITDA, which at 9.15x appears cheap, but the EBITDA is distorted by one-time charges and labor cost inflation, obscuring true earning power, as per recent filings.
Investors often use EV/EBITDA to value healthcare facilities, but for Acadia, this ratio is currently misleading. The TTM EBITDA is depressed by the massive Q4 2025 charge, making the multiple appear artificially low. Conversely, the forward EV/EBITDA of 17.18x suggests that the market expects a recovery, but this may be overly optimistic if labor costs remain elevated. A better metric is EV/EBITDAR (earnings before interest, taxes, depreciation, amortization, and rent), which normalizes for the high fixed costs of facility leases and labor. Alternatively, analysts should focus on cash flow-based metrics like EV/OCF, which better captures the company's ability to generate cash from operations, as evidenced by the divergence between cumulative OCF of $385.5M and cumulative net income of -$924.7M over the past ten quarters.